Shilpa Gupta, MD - Cleveland Clinic discusses Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers - Abstract 5019 and Abstract 5020
Trending
HCRN GU14-182: Randomized Double-Blind Phase II Study Of Maintenance Pembrolizumab VS Placebo After First-Line Chemotherapy In Patients with mUC.
HCRN GU14-182 Questions: OS Is The Endpoint Needed To See To Impact Practice, Phase 3 Study Will Answer Future Questions
Latest Videos
Petros Grivas, MD, PhD @SeattleCCA #UrothelialCancer FDA Approves Avelumab (BAVENCIO) as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carci...
Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers - Abstract 5019 and Abstract 5020 - Abstract 5019 - Shilpa Gupta MD - Cleveland Clinic @CleClinicMD #bladder...
Seth Lerner, MD on Technical Aspects to Delivering the Drug in Urothelial Cancer @bcmhouston
